• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis.

作者信息

Naidoo Kogieleum, Perumal Rubeshan

机构信息

Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban 4001, South Africa; Medical Research Council-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, University of KwaZulu-Natal, Durban 4001, South Africa.

Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban 4001, South Africa; Medical Research Council-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, University of KwaZulu-Natal, Durban 4001, South Africa.

出版信息

Lancet Infect Dis. 2025 Apr;25(4):366-367. doi: 10.1016/S1473-3099(24)00653-4. Epub 2024 Nov 26.

DOI:10.1016/S1473-3099(24)00653-4
PMID:39612927
Abstract
摘要

相似文献

1
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis.关于含新型方案的喹博地司他治疗药物敏感型肺结核的首批数据。
Lancet Infect Dis. 2025 Apr;25(4):366-367. doi: 10.1016/S1473-3099(24)00653-4. Epub 2024 Nov 26.
2
Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial.喹博地司他与地拉曼尼、贝达喹啉或两者联合用于成人肺结核的安全性、药代动力学及早期杀菌活性：一项随机、活性对照、开放标签试验
Lancet Infect Dis. 2025 Apr;25(4):435-444. doi: 10.1016/S1473-3099(24)00601-7. Epub 2024 Nov 26.
3
Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy.夸巴代匹斯特联合德拉马尼和贝达喹啉治疗药物敏感性肺结核患者的多中心 2b/2c 期、开放标签、随机、剂量探索试验：评估安全性和疗效的方案。
Trials. 2024 Jan 19;25(1):70. doi: 10.1186/s13063-024-07912-5.
4
Quabodepistat (OPC-167832), a Novel Antituberculosis Drug Candidate: Enhancing Oral Bioavailability via Cocrystallization and Mechanistic Analysis of Bioavailability in Two Cocrystals.夸巴代普司他（OPC-167832），一种新型抗结核候选药物：通过共结晶提高口服生物利用度及两种共晶生物利用度的机制分析。
Mol Pharm. 2024 Jan 1;21(1):358-369. doi: 10.1021/acs.molpharmaceut.3c01059. Epub 2023 Dec 15.
5
Crystal structure of a 1:1 co-crystal of quabodepistat (OPC-167832) with 2,5-di-hydroxy-benzoic acid using microcrystal electron diffraction.使用微晶电子衍射法解析夸博地司他（OPC-167832）与2,5-二羟基苯甲酸1:1共晶体的晶体结构。
Acta Crystallogr E Crystallogr Commun. 2023 Sep 19;79(Pt 10):920-922. doi: 10.1107/S2056989023006047. eCollection 2023 Oct 1.
6
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.在抗结核治疗的前 8 周，莫西沙星、贝达喹啉（PA-824）和吡嗪酰胺联合使用的疗效和安全性：一项在药物敏感性或耐药性肺结核患者中进行的 2b 期、开放标签、部分随机试验。
Lancet. 2015 May 2;385(9979):1738-1747. doi: 10.1016/S0140-6736(14)62002-X. Epub 2015 Mar 18.
7
[The effectiveness of pyrazinamide-containing six-month short course chemotherapy].[含吡嗪酰胺的六个月短程化疗的疗效]
Kekkaku. 2000 Nov;75(11):665-73.
8
Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: a clinical trial.含氯法齐明的创新短程方案治疗耐多药结核病的疗效和安全性：一项临床试验。
Emerg Microbes Infect. 2023 Dec;12(1):2187247. doi: 10.1080/22221751.2023.2187247.
9
Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial.优化利福喷丁为基础的方案（RI）和缩短（EN）药物敏感结核病（T）（ORIENT）的治疗时间：一项多中心随机对照试验的适应性无缝设计研究方案。
BMC Infect Dis. 2023 May 8;23(1):300. doi: 10.1186/s12879-023-08264-2.
10
Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.药物敏感型肺结核的短程治疗方案与标准方案对比
Cochrane Database Syst Rev. 2019 Dec 12;12(12):CD012918. doi: 10.1002/14651858.CD012918.pub2.

引用本文的文献

1
Clinical best practices for caring for people with expanded resistance to newer TB drugs.针对对新型结核病药物具有广泛耐药性患者的临床最佳护理实践。
IJTLD Open. 2025 Jun 13;2(6):315-323. doi: 10.5588/ijtldopen.25.0240. eCollection 2025 Jun.